Skip to main content
OpenTrials
Completed

NCT Number: NCT01881490

The ImageKids Study: Developing the pMEDIC and the PICMI

The overall objectives of this study are to develop two indices capable of measuring intestinal damage, and, separately, inflammatory disease activity in Pediatric Crohn's disease by means of Magnetic Resonance Imaging with Enterography protocol (MRE) and pelvic MRI.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shaare Zedek Medical Center

Jerusalem, Israel

About this study

The PICMI Score and the pMEDIC are aimed to be discriminative (at one point in time), evaluative (measuring damage progression over time) and predictive. The indices will be used as endpoint measures in clinical research and also in clinical practice to identify those who are at risk for rapid disease progression and surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children (under 18 years of age) with established diagnosis of CD involving any location by the presence of accepted clinical, radiologic, endoscopic and histologic criteria (33, 34).
  • Enrolment at the time of performing ileocolonoscopy and esophageal-gastroduodenoscopy (EGD) as part of clinical care for any reason.
  • Children will be enrolled at any phase of the disease (at diagnosis and thereafter as required clinically). In order to ensure enough subjects with intestinal damage and since damage is progressing over time, enrolment will be stratified based on disease duration. Enrolment for each stratum of disease duration will be closed after reaching the expected sample size.
  • 20% of enrolled children will be within 3 months of diagnosis.
  • 20% of children will be between 3 months and 2 years.
  • 20% will be 2.01 to 3 years
  • 40% will have disease duration over 3-years.
  • Children may be enrolled in any disease activity state (PCDAI 0-100).

Exclusion criteria

  • Young children requiring anesthesia for lack of cooperation will be excluded (since the enteric contrast cannot be administered during the 2 hours before anesthesia and it is crucial that the contrast be given just prior the test).
  • For the first 120 children only, subjects not expected to be available for 18 month follow-up, will be excluded (the last 120 subjects may be enrolled as they are not followed longitudinally).

Treatment and study plan

MRE

Device

Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)

Other names: MRI, Pelvic MRI

Primary outcomes

  1. Development of MRI-based Index

    Time frame: 3.5 years

    The overall objectives of this study are to develop two indices capable of measuring intestinal damage, and, separately, inflammatory disease activity means of MRE.

    The indices are aimed to be discriminative, evaluative and predictive. they will be used as endpoint measures in clinical research and also in clinical practice to identify those who are at risk for rapid disease progression and surgery. The data collected will be analyzed and scored by both the radiologists and the gastroenterologists. On the basis of these scores, 2 or 3 contending versions of each index will be then subjected to head-to-head evaluation by enrolling another cohort of 120 children undergoing colonoscopy and MRE/pelvic MRI. The best version for each index will be selected according to its performance in the validity, reliability and responsiveness testing. The second group of patients will not be followed longitudinally.

Secondary outcomes

  1. Exploratory

    Time frame: 3.5 years

    To describe the 18-month progression rate of intestinal damage in pediatric Crohn's disease, stratified by the different medications used, and disease duration at enrolment.

  2. Exploratory

    Time frame: 3.5 Years

    To identify biological and clinical markers, predictive of intestinal damage.

Sponsors and collaborators

Lead sponsor

Shaare Zedek Medical Center

Other

Collaborators

  • Alberta Children
  • C.S. Mott Children's Hospital
  • Children's Hospital Medical Center, Cincinnati
  • Children's Hospital of Eastern Ontario
  • Children's Hospital of Philadelphia
  • Connecticut Children's Medical Center
  • Dr. von Hauner Children's Hospital
  • Erasmus Medical Center
  • Hasbro Children's Hospital
  • Hospital Materno-Infantil de Málaga
  • Hospital Sant Joan de Deu
  • Hôpital Necker-Enfants Malades
  • IWK Health Centre
  • Klinikum Stuttgart
  • Leiden University Medical Center
  • McMaster Children's Hospital
  • Nationwide Children's Hospital
  • Rambam Health Care Campus
  • Royal Children's Hospital
  • Schneider Children
  • Sheba Medical Center
  • Soroka University Medical Center
  • Sydney Children's Hospitals Network
  • The Hospital for Sick Children
  • Yorkhill Hospital

Registry information

Official study title

The ImageKids Study: Developing the Pediatric MR Enterography-based Damage Index in Crohn's Disease (pMEDIC) and the Pediatric Inflammatory Crohn's MRE Index (PICMI)

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Jun 19, 2013
Registry last updated
May 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.